ERBB2 and non-small cell lung carcinoma: In an ongoing study by Meric-Bernstam et al. (NCT02892123), remarkable results are recorded while the investigation of zanidatamab for multiple HER2-positive malignancies including BTC, colorectal, breast and ovarian cancers, GEA, and non-small cell lung carcinoma (NSCLC).